Abstract
Agitation is commonly seen in acute schizophrenic patients and core symptoms include a wide range of symptom. It requires rapid and effective treatment approaches in order to protect patient and caregiver from potential injury. Clinicians decision of pharmacological treatment should be individualized to the needs and circumstances of the patient. Benzodiazepines, typical antipsychotics, and combinations of typical antipsychotics and benzodiazepines have been widely used as treatment options. Atypical antipsychotics have clear advantages over the typical drugs as they generally show a much better safety and tolerability profile, particularly to EPS and related side effects, however clinical perception regarding efficacy in treating acutely agitated psychotic patient is controversial. New intramuscular atypical antipsychotic formulations offer evidence of being at least as effective as typical antipsychotics in controlling agitation. Therefore, they should be considered as first line therapy in agitated schizophrenic patients.
Keywords: atypical antipsychotics, intramuscular, schizophrenia, agitation
Current Pharmaceutical Design
Title: Pharmacological Management of Acutely Agitated Schizophrenic Patients
Volume: 11 Issue: 19
Author(s): L. San, B. Arranz and R. Escobar
Affiliation:
Keywords: atypical antipsychotics, intramuscular, schizophrenia, agitation
Abstract: Agitation is commonly seen in acute schizophrenic patients and core symptoms include a wide range of symptom. It requires rapid and effective treatment approaches in order to protect patient and caregiver from potential injury. Clinicians decision of pharmacological treatment should be individualized to the needs and circumstances of the patient. Benzodiazepines, typical antipsychotics, and combinations of typical antipsychotics and benzodiazepines have been widely used as treatment options. Atypical antipsychotics have clear advantages over the typical drugs as they generally show a much better safety and tolerability profile, particularly to EPS and related side effects, however clinical perception regarding efficacy in treating acutely agitated psychotic patient is controversial. New intramuscular atypical antipsychotic formulations offer evidence of being at least as effective as typical antipsychotics in controlling agitation. Therefore, they should be considered as first line therapy in agitated schizophrenic patients.
Export Options
About this article
Cite this article as:
San L., Arranz B. and Escobar R., Pharmacological Management of Acutely Agitated Schizophrenic Patients, Current Pharmaceutical Design 2005; 11 (19) . https://dx.doi.org/10.2174/1381612054367472
DOI https://dx.doi.org/10.2174/1381612054367472 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Medicinal Chemistry of 2,2,4-Substituted Morpholines
Current Medicinal Chemistry Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape
Current Neuropharmacology Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design The Mini-Mental Parkinson’s (MMP) as a Cognitive Screening Tool in People with Parkinson’s Disease
Current Aging Science Neuroimaging of Narcolepsy
CNS & Neurological Disorders - Drug Targets FKBP Ligands as Novel Therapeutics for Neurological Disorders
Mini-Reviews in Medicinal Chemistry Zinc Supplementation in Preterm Neonates with Jaundice: Is it Beneficial?
Endocrine, Metabolic & Immune Disorders - Drug Targets Elevated Homocysteine Levels in Parkinsons Disease: Is there Anything Besides L-Dopa Treatment?
Current Medicinal Chemistry Nonmuscle Myosin Heavy Chain and Histone H3 are Intracellular Binding Partners of Lithospermic Acid B and Mediate its Antiproliferative Effect on VSMCs
Current Medicinal Chemistry Anomalies of Self in First-Episode Psychosis
Current Psychiatry Reviews Memories are Made of This (Perhaps): A Review of Serotonin 5-HT6 Receptor Ligands and Their Biological Functions
Current Topics in Medicinal Chemistry Pathophysiology of Airway Colonization in Critically ill COPD Patient
Current Drug Targets Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Therapeutics and Carriers: The Dual Role of Proteins in Nanoparticles for Ocular Delivery
Current Topics in Medicinal Chemistry Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors
Current Medicinal Chemistry Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery The Impact of Omega-3 Fatty Acids on Osteoporosis
Current Pharmaceutical Design